Hypoxia-inducible factor for the treatment of anemia in chronic kidney disease

Abstract

Studies in the field of oxygen-dependent regulation of erythropoiesis provided new data on the pathogenesis of anemia associated with chronic kidney disease, which led to the development of therapeutic agents for treatment. A new class of agents for the treatment of anemia in chronic kidney disease are prolyl hydroxylase inhibitors, which stabilize hypoxia-inducible factor that is the key regulator of erythropoiesis and iron metabolism. Currently, drugs such as roxadustat (FG-4592), vadadustat (AKB-6548), daprodustat (GSK1278863) are undergoing phase III clinical trials, and molidustat (BAY 85-3934) — phase II.

Keywords

• anemia
• chronic kidney disease
• hypoxia-inducible factor
• prolyl hydroxylase inhibitor
• roxadustat
• vadadustat
• daprodustat
• molidustat
• review